A Closer Look: Ambrx Doubles Down In China With Hisun Deal
This article was originally published in PharmAsia News
San Diego-based Ambrx is aggressively striking deals with companies in China. PharmAsia News takes a closer look at a recent deal with Hisun and adds background to its growing ties to Big Pharma.
You may also be interested in...
Unlike most work in antibody-drug conjugates, however, the collaboration will not focus on oncology but on a broad array of undisclosed targets that may be applicable in a wide variety of indications.
Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.